Lexicon Pharmaceuticals Inc (LXRX) — Cash Flow-to-Debt Ratio
Lexicon Pharmaceuticals Inc (LXRX) has a Cash Flow-to-Debt Ratio of -0.22x as of March 2026, meaning its operating cash flow of $-14.73 Million could theoretically repay 0% of its total liabilities ($65.96 Million) in one year. See how financially flexible is Lexicon Pharmaceuticals Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Lexicon Pharmaceuticals Inc Cash Flow-to-Debt Ratio (1999–2025)
Historical debt coverage capacity for Lexicon Pharmaceuticals Inc across 27 annual periods. For the full cash flow conversion analysis, see how efficiently does Lexicon Pharmaceuticals Inc generate cash.
Annual Cash Flow-to-Debt Ratio for Lexicon Pharmaceuticals Inc (1999–2025)
Year-by-year debt coverage analysis for Lexicon Pharmaceuticals Inc. Check LXRX operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.88x | $-67.85 Million | $77.45 Million | ▲ +25.3% |
| 2024 | -1.17x | $-178.78 Million | $152.47 Million | ▲ +1.3% |
| 2023 | -1.19x | $-161.90 Million | $136.32 Million | ▼ -3.2% |
| 2022 | -1.15x | $-88.85 Million | $77.17 Million | ▲ +69.2% |
| 2021 | -3.73x | $-87.02 Million | $23.31 Million | ▼ -23.8% |
| 2020 | -3.02x | $-142.97 Million | $47.42 Million | ▼ -896.4% |
| 2019 | 0.38x | $113.81 Million | $300.61 Million | ▲ +179.1% |
| 2018 | -0.48x | $-148.61 Million | $310.54 Million | ▲ +0.8% |
| 2017 | -0.48x | $-185.39 Million | $384.44 Million | ▲ +12.6% |
| 2016 | -0.55x | $-175.63 Million | $318.22 Million | ▼ -210.2% |
| 2015 | 0.50x | $184.78 Million | $368.98 Million | ▲ +224.1% |
| 2014 | -0.40x | $-75.62 Million | $187.36 Million | ▲ +53.9% |
| 2013 | -0.88x | $-91.08 Million | $104.00 Million | ▲ +2.6% |
| 2012 | -0.90x | $-94.46 Million | $105.10 Million | ▼ -35.9% |
| 2011 | -0.66x | $-87.94 Million | $132.94 Million | ▲ +3.7% |
| 2010 | -0.69x | $-82.37 Million | $119.86 Million | ▲ +27.2% |
| 2009 | -0.94x | $-89.02 Million | $94.26 Million | ▲ +35.1% |
| 2008 | -1.46x | $-95.60 Million | $65.68 Million | ▼ -62.0% |
| 2007 | -0.90x | $-74.32 Million | $82.72 Million | ▼ -65.4% |
| 2006 | -0.54x | $-56.91 Million | $104.77 Million | ▼ -408.0% |
| 2005 | 0.18x | $23.44 Million | $132.91 Million | ▲ +137.7% |
| 2004 | -0.47x | $-42.26 Million | $90.39 Million | ▼ -614.8% |
| 2003 | -0.07x | $-7.72 Million | $117.98 Million | ▲ +92.8% |
| 2002 | -0.90x | $-28.79 Million | $31.87 Million | ▼ -8.6% |
| 2001 | -0.83x | $-17.99 Million | $21.62 Million | ▼ -624.1% |
| 2000 | -0.11x | $-1.50 Million | $13.06 Million | ▲ +83.1% |
| 1999 | -0.68x | $-9.60 Million | $14.10 Million | — |